These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28432573)

  • 21. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statin treatment and carotid plaque composition: a review of clinical studies.
    Puato M; Zambon A; Faggin E; Rattazzi M; Pauletto P
    Curr Vasc Pharmacol; 2014 May; 12(3):518-26. PubMed ID: 23092412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.
    Yogo M; Sasaki M; Ayaori M; Kihara T; Sato H; Takiguchi S; Uto-Kondo H; Yakushiji E; Nakaya K; Komatsu T; Momiyama Y; Nagata M; Mochio S; Iguchi Y; Ikewaki K
    Atherosclerosis; 2014 Jan; 232(1):31-9. PubMed ID: 24401214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for hyperlipidaemia: an update.
    Florentin M; Kostapanos MS; Kei A; Elisaf MS
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):471-88. PubMed ID: 25356785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lower is better--the contemporary concept of low-density lipoprotein lowering in the preventive management of cardiovascular risk: does this apply to all patients?
    Nixon JV
    Prev Cardiol; 2006; 9(4):219-25; quiz 226-7. PubMed ID: 17085985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia.
    Schimmenti C; Sucato V; Manzone E; Cancellieri G; Mortillaro F; Novo G; Galassi AR; Venturella F
    Coron Artery Dis; 2021 Jun; 32(4):340-344. PubMed ID: 33229935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid-lowering therapy in low-risk patients.
    Pearson TA
    JAMA; 1998 May; 279(20):1659-61. PubMed ID: 9613918
    [No Abstract]   [Full Text] [Related]  

  • 32. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL.
    Averna M; Stroes E;
    Atheroscler Suppl; 2017 Apr; 26():16-24. PubMed ID: 28434480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD?
    Hochholzer W; Giugliano RP
    Curr Atheroscler Rep; 2013 Jan; 15(1):290. PubMed ID: 23242605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
    Negi S; Ballantyne CM
    J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets.
    Toth PP; Grabner M; Punekar RS; Quimbo RA; Cziraky MJ; Jacobson TA
    Atherosclerosis; 2014 Aug; 235(2):585-91. PubMed ID: 24956532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.